Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Androgen insensitivity syndrome (AIS) results from androgen receptor dysfunction and is a
common cause of disorder of sex development. The AIS phenotype largely depends on the …

In many aspects of life, epigenetics, or the altering of phenotype without changes in
sequences, play an essential role in biological function. A vast number of epigenomic …

ChIPseeker is an R package for annotating ChIP-seq data analysis. It supports annotating
ChIP peaks and provides functions to visualize ChIP peaks coverage over chromosomes …

Alterations in DNA repair promote tumor development, but the impact on tumor progression
is poorly understood. Here, discovery of a biochemical circuit linking hormone signaling to …

Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of
prostate cancer. To compare the genomic alteration landscapes of EO-PCA with" …

Androgen receptor splice variant‐7 (AR‐V7), one of the major driving factors, is the most
attractive drug target in castration‐resistant prostate cancer (CRPC). Currently, no available …

Background: The hypoxia marker pimonidazole is a candidate biomarker of cancer
aggressiveness. We investigated the transcriptional programme associated with …

The androgen receptor (AR) signaling pathway is involved in the emergence of castration-
resistant prostate cancer (CRPC). Here, we identified several androgen-regulated …

Prostate cancer treatment is dominated by strategies to control androgen receptor (AR)
activity. AR has an impact on prostate cancer development through the regulation of not only …